Morgan Stanley lowers Shenzhen New Industries' target price to Rmb56 but maintains Overweight

Overview

Morgan Stanley published a risk-reward update on Shenzhen New Industries (300832.SZ). Ahead of 2Q results, the report adjusts its model and maintains the long-term investment thesis for the company as China's leading pure-play CLIA player, but lowers the DCF target price from Rmb61 to Rmb56 due to deeper short-term healthcare reform and regulatory uncertainty facing China's IVD industry.

Core views

The report believes Shenzhen New Industries has a comprehensive testing menu, in-house R&D capabilities, a broad commercialization network, and a strong historical execution record. CLIA reagent VBP implementation has been advancing since 2024 and, under relatively moderate rules and rational bidding, could accelerate domestic substitution, benefiting domestic leaders over the long term while keeping pricing and margin impacts manageable. Overseas expansion has accelerated in recent years, with a long growth runway and high geographic diversification; geopolitical risks are considered manageable. Valuation is not high relative to the company's structural growth prospects, and near-term headwinds have been partially reflected in the share price.

Analysis framework

The report applies a risk-reward framework, presenting bull, base, and bear cases and combining DCF valuation, EPS estimate revisions, revenue CAGR, margins, VBP impact, domestic installation recovery, and overseas expansion progress to assess the target price and rating. The base-case target price is Rmb56, the bull-case target price is Rmb70, and the bear-case target price is Rmb32.

Methodology notes

• Valuation methodDCF

  Discounted cash flow valuation

  The report uses a DCF methodology, assuming a WACC of 9.0% and a perpetual growth rate of 3.0%, with the model beginning in 2026. The target price cut is mainly driven by more conservative medium- to long-term EPS assumptions and a higher WACC reflecting increased regulatory uncertainty.

• Scenario analysisRisk-reward framework

  Bull, base, and bear cases

  The bull case assumes revenue CAGR above 15% from 2025-2027 accompanied by significant margin expansion; the base case assumes revenue CAGR of approximately 10% with broadly stable margins; and the bear case assumes revenue CAGR below 5% with margin deterioration.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Shenzhen New Industries (300832.SZ)

  Research subject; China's leading pure-play CLIA company

  Strengths

  Comprehensive testing menu, in-house R&D, commercial network, domestic substitution opportunity, accelerating overseas expansion, and valuation that is not high relative to structural growth.

  Weaknesses

  Uncertain short-term recovery in China's IVD industry, pricing and margin pressure from VBP and healthcare reform, and lowered 2027-2030 EPS estimates.

  Comparison

  Relative to peers, the report assumes a WACC of 9.0% and believes the company has leadership advantages in CLIA domestic substitution and overseas expansion.

  Risks

  Intensifying competition, unfavorable VBP rules and bidding results, continued impact from anti-corruption efforts, overseas expansion below expectations, and trade friction involving the EU and certain emerging markets.

Key data

• Target priceRmb56.00Lowered from Rmb61.00.
• Bull caseRmb70.00Lowered from Rmb78.00, corresponding to 28.9x 2027e bull-case EPS.
• Base caseRmb56.00Corresponding to 23.1x 2027e base-case EPS.
• Bear caseRmb32.00Lowered from Rmb35.00, corresponding to 16.2x 2027e bear-case EPS.
• Current share priceRmb42.01Closing price on July 9, 2026.
• 2026e EPSRmb2.20Previously Rmb2.22.
• 2027e EPSRmb2.42Previously Rmb2.46.
• 2028e EPSRmb2.67Previously Rmb2.73.
• 2026e IVD reagent sales growth10.4%Key earnings input.
• 2027e IVD analyzer sales growth13.4%Key earnings input.

Impact & implications

The target price cut indicates that the analyst is more cautious about near-term demand and the regulatory environment in China's IVD industry, but maintaining Overweight indicates that the long-term structural thesis remains intact. If VBP implementation is moderate, domestic installation recovery proceeds smoothly, and overseas growth continues, the company may still offset pricing pressure through share gains and product mix improvement; if the impact of anti-corruption efforts, VBP, or competitive pressure exceeds expectations, revenue and margins could fall into the bear-case scenario.

Risks

• VBP rules and bidding results fall short of expectations, leading to greater pricing and margin pressure.
• The negative impact of anti-corruption campaigns on domestic analyzer installations and reagent sales persists.
• Intensifying competition slows or stalls SNIBE's market share gains.
• Overseas expansion falls below expectations, while upfront investment weighs on margins.
• Potential trade friction involving the EU and certain emerging markets affects overseas growth.

What to watch

• VBP implementation results.
• Analyzer and automated line installation cadence.
• Overseas expansion progress.
• Quarterly results.
• Pace of recovery in China's CLIA industry.
• Approval and ramp-up cadence of key new products.